Shiva Dahal‐Koirala

Protocol for Non-viral HDR-based CRISPR/Cas9 platform for small custom editing in primary T cells

This paper presents a non-viral HDR-based CRISPR/Cas9 protocol for editing primary T cells with up to 80% HDR efficiency, targeting small pathogenic variants in patient and healthy donor cells.

A predisposing effect of HLA class II genes in celiac disease by skewing the naive CD4+ T-cell receptor repertoire

The paper shows HLA-DQ2.5 variants increase frequencies of TCR genes involved in gluten epitope recognition in CeD patients, linking HLA to disease by shaping the naive TCR repertoire.

NFATC2 in pancreatic cancer-associated fibroblasts predicts treatment response and facilitates ERBB-targeted therapies

The paper identifies NFATC2-expressing cancer-associated fibroblasts in PDAC that improve treatment response and enhance ERBB-targeted therapies.

Editing of ADA2 Point Mutation in Human Hematopoietic Stem Cells

This paper edits the ADA2 p.R169Q mutation in human hematopoietic stem cells using CRISPR-Cas9 and HDR, showing improved efficiency with NHEJ inhibitors but increased chromosomal deletions.

T cell correction pipeline for Inborn Errors of Immunity

This paper presents a T cell gene correction pipeline using CRISPR/Cas9 and HDR to correct monogenic mutations in IEI models, achieving up to 80% bi-allelic editing with no detectable off-target effects.